Physician profile
George Dickstein
NPI 1720054356
$21,138.02
in general payments reported to CMS, 2019-2025
21 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $15.43 · 2021: $11.05 · 2022: $1,666 · 2023: $302 · 2024: $348 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $1,145 · Travel and Lodging: $1,103 · Education: $99.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,864.00 |
| Food and Beverage | $1,145.02 |
| Travel and Lodging | $1,103.26 |
| Education | $99.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18,148.36 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,666.00 | 2022 | |
| Janssen Biotech, INC. | $271.14 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $262.52 | 2019-2025 | |
| Celgene Corporation | $108.62 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $104.32 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $100.88 | 2019-2020 | |
| Abbvie INC. | $97.09 | 2023-2025 | Skyrizi, Rinvoq |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Madrigal Pharmaceuticals | $68.25 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $57.37 | 2019-2024 | |
| Ucb, INC. | $36.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.68 | 2023 | Entyvio |
| Amgen INC. | $31.03 | 2023 | Avsola |
| Concordia Pharmaceuticals INC. | $25.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.52 | 2024 | |
| Lilly USA, LLC | $15.33 | 2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $14.16 | 2023 | Gi Genius |
| Endogastric Solutions, INC | $13.30 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dickstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.